JP2000511043A - ノッチ経路を用いる最終未分化細胞の操作 - Google Patents

ノッチ経路を用いる最終未分化細胞の操作

Info

Publication number: JP2000511043A
Authority: JP; Japan
Prior art keywords: cells; notch; cell; progenitor cells; progenitor
Prior art date: 1995-09-29
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Withdrawn

Application number

JP09513747A

Other languages

English (en)

Japanese (ja)

Other versions

JP2000511043A5 (2

Inventor

アルタヴァニス−ツァコナス，スピリドン

フォルティニ，マーク，イー．

健治松野

Original Assignee

エールユニバーシティー

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-09-29

Filing date

1996-09-27

Publication date

2000-08-29

1996-09-27 Application filed by エールユニバーシティー filed Critical エールユニバーシティー

2000-08-29 Publication of JP2000511043A publication Critical patent/JP2000511043A/ja

2004-09-30 Publication of JP2000511043A5 publication Critical patent/JP2000511043A5/ja

Status Withdrawn legal-status Critical Current

Links

108010070047 Notch Receptors Proteins 0.000 title claims description 384
102000005650 Notch Receptors Human genes 0.000 title claims description 382
230000037361 pathway Effects 0.000 title claims description 90
210000004027 cell Anatomy 0.000 claims abstract description 470
210000000130 stem cell Anatomy 0.000 claims abstract description 250
238000000034 method Methods 0.000 claims abstract description 137
239000000556 agonist Substances 0.000 claims abstract description 63
108090000623 proteins and genes Proteins 0.000 claims description 144
230000004069 differentiation Effects 0.000 claims description 98
102000004169 proteins and genes Human genes 0.000 claims description 57
239000002243 precursor Substances 0.000 claims description 43
239000003446 ligand Substances 0.000 claims description 41
239000012634 fragment Substances 0.000 claims description 36
239000005557 antagonist Substances 0.000 claims description 35
102000039446 nucleic acids Human genes 0.000 claims description 30
108020004707 nucleic acids Proteins 0.000 claims description 30
150000007523 nucleic acids Chemical class 0.000 claims description 30
230000000694 effects Effects 0.000 claims description 28
230000010261 cell growth Effects 0.000 claims description 25
210000003958 hematopoietic stem cell Anatomy 0.000 claims description 24
238000000338 in vitro Methods 0.000 claims description 24
230000027455 binding Effects 0.000 claims description 21
238000009739 binding Methods 0.000 claims description 21
230000019491 signal transduction Effects 0.000 claims description 21
230000003834 intracellular effect Effects 0.000 claims description 19
210000002569 neuron Anatomy 0.000 claims description 19
210000003716 mesoderm Anatomy 0.000 claims description 17
102000011842 Serrate-Jagged Proteins Human genes 0.000 claims description 16
108010036039 Serrate-Jagged Proteins Proteins 0.000 claims description 16
230000024245 cell differentiation Effects 0.000 claims description 15
230000012010 growth Effects 0.000 claims description 15
230000001404 mediated effect Effects 0.000 claims description 15
210000003491 skin Anatomy 0.000 claims description 14
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 13
230000001939 inductive effect Effects 0.000 claims description 13
210000003981 ectoderm Anatomy 0.000 claims description 10
210000002919 epithelial cell Anatomy 0.000 claims description 10
210000004185 liver Anatomy 0.000 claims description 10
238000011282 treatment Methods 0.000 claims description 10
201000010099 disease Diseases 0.000 claims description 7
208000035475 disorder Diseases 0.000 claims description 6
210000001900 endoderm Anatomy 0.000 claims description 6
210000001612 chondrocyte Anatomy 0.000 claims description 5
230000001086 cytosolic effect Effects 0.000 claims description 5
230000002401 inhibitory effect Effects 0.000 claims description 5
210000000805 cytoplasm Anatomy 0.000 claims description 3
230000002440 hepatic effect Effects 0.000 claims description 3
210000000963 osteoblast Anatomy 0.000 claims description 3
230000001737 promoting effect Effects 0.000 claims description 3
238000012258 culturing Methods 0.000 claims description 2
101000914947 Bungarus multicinctus Long neurotoxin homolog TA-bm16 Proteins 0.000 claims 4
210000005155 neural progenitor cell Anatomy 0.000 claims 2
101100156752 Caenorhabditis elegans cwn-1 gene Proteins 0.000 claims 1
102000052547 Wnt-1 Human genes 0.000 claims 1
108700020987 Wnt-1 Proteins 0.000 claims 1
210000000663 muscle cell Anatomy 0.000 claims 1
238000001415 gene therapy Methods 0.000 abstract description 25
230000002062 proliferating effect Effects 0.000 abstract description 11
230000008929 regeneration Effects 0.000 abstract description 6
238000011069 regeneration method Methods 0.000 abstract description 6
238000009256 replacement therapy Methods 0.000 abstract description 2
230000006870 function Effects 0.000 description 78
230000014509 gene expression Effects 0.000 description 70
230000004913 activation Effects 0.000 description 51
230000018109 developmental process Effects 0.000 description 48
235000018102 proteins Nutrition 0.000 description 46
238000011161 development Methods 0.000 description 45
210000001519 tissue Anatomy 0.000 description 45
230000003993 interaction Effects 0.000 description 29
241000255581 Drosophila <fruit fly, genus> Species 0.000 description 23
210000004940 nucleus Anatomy 0.000 description 23
210000001508 eye Anatomy 0.000 description 22
230000011664 signaling Effects 0.000 description 20
101100342473 Drosophila melanogaster Raf gene Proteins 0.000 description 19
102000016662 ELAV Proteins Human genes 0.000 description 19
108010053101 ELAV Proteins Proteins 0.000 description 19
108091034117 Oligonucleotide Proteins 0.000 description 19
101100523543 Rattus norvegicus Raf1 gene Proteins 0.000 description 19
101100523549 Xenopus laevis raf1 gene Proteins 0.000 description 19
101150037250 Zhx2 gene Proteins 0.000 description 19
238000001727 in vivo Methods 0.000 description 19
101150045048 Ras85D gene Proteins 0.000 description 18
230000001537 neural effect Effects 0.000 description 18
210000001185 bone marrow Anatomy 0.000 description 16
239000013598 vector Substances 0.000 description 16
102000008102 Ankyrins Human genes 0.000 description 14
108010049777 Ankyrins Proteins 0.000 description 14
230000003213 activating effect Effects 0.000 description 14
230000005913 Notch signaling pathway Effects 0.000 description 13
210000004556 brain Anatomy 0.000 description 13
239000000047 product Substances 0.000 description 13
230000035755 proliferation Effects 0.000 description 13
108700037638 Neurogenic locus notch homolog protein 1 Proteins 0.000 description 12
102100023181 Neurogenic locus notch homolog protein 1 Human genes 0.000 description 12
241000700159 Rattus Species 0.000 description 12
210000002615 epidermis Anatomy 0.000 description 12
239000000203 mixture Substances 0.000 description 12
230000000692 anti-sense effect Effects 0.000 description 11
230000002068 genetic effect Effects 0.000 description 11
239000010410 layer Substances 0.000 description 11
238000004519 manufacturing process Methods 0.000 description 11
230000004044 response Effects 0.000 description 11
241001465754 Metazoa Species 0.000 description 10
230000015572 biosynthetic process Effects 0.000 description 10
239000003814 drug Substances 0.000 description 10
210000000981 epithelium Anatomy 0.000 description 10
238000002955 isolation Methods 0.000 description 10
238000002054 transplantation Methods 0.000 description 10
238000003556 assay Methods 0.000 description 9
230000001605 fetal effect Effects 0.000 description 9
210000004209 hair Anatomy 0.000 description 9
210000004379 membrane Anatomy 0.000 description 9
239000012528 membrane Substances 0.000 description 9
238000012546 transfer Methods 0.000 description 9
108091032973 (ribonucleotides)n+m Proteins 0.000 description 8
210000000056 organ Anatomy 0.000 description 8
108091008598 receptor tyrosine kinases Proteins 0.000 description 8
102000005962 receptors Human genes 0.000 description 8
108020003175 receptors Proteins 0.000 description 8
238000010186 staining Methods 0.000 description 8
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 7
239000000427 antigen Substances 0.000 description 7
108091007433 antigens Proteins 0.000 description 7
102000036639 antigens Human genes 0.000 description 7
210000000988 bone and bone Anatomy 0.000 description 7
210000002257 embryonic structure Anatomy 0.000 description 7
210000003754 fetus Anatomy 0.000 description 7
210000001035 gastrointestinal tract Anatomy 0.000 description 7
239000003102 growth factor Substances 0.000 description 7
230000006698 induction Effects 0.000 description 7
210000004072 lung Anatomy 0.000 description 7
230000000394 mitotic effect Effects 0.000 description 7
108090000765 processed proteins & peptides Proteins 0.000 description 7
210000002763 pyramidal cell Anatomy 0.000 description 7
102000027426 receptor tyrosine kinases Human genes 0.000 description 7
210000001525 retina Anatomy 0.000 description 7
230000002207 retinal effect Effects 0.000 description 7
239000002253 acid Substances 0.000 description 6
239000003795 chemical substances by application Substances 0.000 description 6
238000002347 injection Methods 0.000 description 6
239000007924 injection Substances 0.000 description 6
210000001982 neural crest cell Anatomy 0.000 description 6
230000008569 process Effects 0.000 description 6
230000001177 retroviral effect Effects 0.000 description 6
230000002441 reversible effect Effects 0.000 description 6
230000001225 therapeutic effect Effects 0.000 description 6
241000255925 Diptera Species 0.000 description 5
241000282412 Homo Species 0.000 description 5
241000699666 Mus <mouse, genus> Species 0.000 description 5
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 5
241000269370 Xenopus <genus> Species 0.000 description 5
238000004458 analytical method Methods 0.000 description 5
239000000074 antisense oligonucleotide Substances 0.000 description 5
238000012230 antisense oligonucleotides Methods 0.000 description 5
210000002798 bone marrow cell Anatomy 0.000 description 5
210000000845 cartilage Anatomy 0.000 description 5
230000011712 cell development Effects 0.000 description 5
230000004663 cell proliferation Effects 0.000 description 5
210000003169 central nervous system Anatomy 0.000 description 5
239000003623 enhancer Substances 0.000 description 5
238000002474 experimental method Methods 0.000 description 5
210000001161 mammalian embryo Anatomy 0.000 description 5
230000007246 mechanism Effects 0.000 description 5
239000002609 medium Substances 0.000 description 5
210000002901 mesenchymal stem cell Anatomy 0.000 description 5
MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 5
239000002773 nucleotide Substances 0.000 description 5
125000003729 nucleotide group Chemical group 0.000 description 5
239000008194 pharmaceutical composition Substances 0.000 description 5
210000000278 spinal cord Anatomy 0.000 description 5
239000000126 substance Substances 0.000 description 5
229940124597 therapeutic agent Drugs 0.000 description 5
238000013518 transcription Methods 0.000 description 5
230000035897 transcription Effects 0.000 description 5
230000001960 triggered effect Effects 0.000 description 5
241000701161 unidentified adenovirus Species 0.000 description 5
102000001301 EGF receptor Human genes 0.000 description 4
108060006698 EGF receptor Proteins 0.000 description 4
241000287828 Gallus gallus Species 0.000 description 4
ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 4
241000251539 Vertebrata <Metazoa> Species 0.000 description 4
241000700605 Viruses Species 0.000 description 4
239000002671 adjuvant Substances 0.000 description 4
230000005540 biological transmission Effects 0.000 description 4
210000004369 blood Anatomy 0.000 description 4
239000008280 blood Substances 0.000 description 4
238000004113 cell culture Methods 0.000 description 4
235000013330 chicken meat Nutrition 0.000 description 4
230000004186 co-expression Effects 0.000 description 4
238000004624 confocal microscopy Methods 0.000 description 4
230000000875 corresponding effect Effects 0.000 description 4
238000010790 dilution Methods 0.000 description 4
239000012895 dilution Substances 0.000 description 4
VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 4
229940079593 drug Drugs 0.000 description 4
210000001339 epidermal cell Anatomy 0.000 description 4
210000003780 hair follicle Anatomy 0.000 description 4
210000000777 hematopoietic system Anatomy 0.000 description 4
230000000968 intestinal effect Effects 0.000 description 4
230000011278 mitosis Effects 0.000 description 4
230000035772 mutation Effects 0.000 description 4
210000000653 nervous system Anatomy 0.000 description 4
239000000816 peptidomimetic Substances 0.000 description 4
102000004196 processed proteins & peptides Human genes 0.000 description 4
230000006798 recombination Effects 0.000 description 4
238000005215 recombination Methods 0.000 description 4
230000001105 regulatory effect Effects 0.000 description 4
210000001116 retinal neuron Anatomy 0.000 description 4
238000012552 review Methods 0.000 description 4
241000894007 species Species 0.000 description 4
238000012360 testing method Methods 0.000 description 4
RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 4
230000009261 transgenic effect Effects 0.000 description 4
101001120236 Crotalus durissus cumanensis Basic phospholipase A2 10 Proteins 0.000 description 3
108020004414 DNA Proteins 0.000 description 3
102000052510 DNA-Binding Proteins Human genes 0.000 description 3
101710096438 DNA-binding protein Proteins 0.000 description 3
101001053785 Drosophila melanogaster Dual specificity mitogen-activated protein kinase kinase dSOR1 Proteins 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
101100118545 Holotrichia diomphalia EGF-like gene Proteins 0.000 description 3
241000124008 Mammalia Species 0.000 description 3
241000699670 Mus sp. Species 0.000 description 3
206010028980 Neoplasm Diseases 0.000 description 3
108010029755 Notch1 Receptor Proteins 0.000 description 3
102000001759 Notch1 Receptor Human genes 0.000 description 3
102100033237 Pro-epidermal growth factor Human genes 0.000 description 3
102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 3
108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 3
208000027418 Wounds and injury Diseases 0.000 description 3
230000009471 action Effects 0.000 description 3
101150041759 boss gene Proteins 0.000 description 3
-1 carboxyhydroxylmethyl Chemical group 0.000 description 3
239000006143 cell culture medium Substances 0.000 description 3
239000006285 cell suspension Substances 0.000 description 3
230000001413 cellular effect Effects 0.000 description 3
230000005754 cellular signaling Effects 0.000 description 3
239000003153 chemical reaction reagent Substances 0.000 description 3
239000003184 complementary RNA Substances 0.000 description 3
230000007812 deficiency Effects 0.000 description 3
238000010586 diagram Methods 0.000 description 3
230000029087 digestion Effects 0.000 description 3
230000013020 embryo development Effects 0.000 description 3
238000005516 engineering process Methods 0.000 description 3
230000002496 gastric effect Effects 0.000 description 3
230000011132 hemopoiesis Effects 0.000 description 3
210000003494 hepatocyte Anatomy 0.000 description 3
210000004408 hybridoma Anatomy 0.000 description 3
238000001990 intravenous administration Methods 0.000 description 3
210000003292 kidney cell Anatomy 0.000 description 3
230000007774 longterm Effects 0.000 description 3
238000012986 modification Methods 0.000 description 3
230000004048 modification Effects 0.000 description 3
230000004001 molecular interaction Effects 0.000 description 3
210000001178 neural stem cell Anatomy 0.000 description 3
210000000276 neural tube Anatomy 0.000 description 3
210000001428 peripheral nervous system Anatomy 0.000 description 3
229920001184 polypeptide Polymers 0.000 description 3
238000011160 research Methods 0.000 description 3
239000000523 sample Substances 0.000 description 3
238000000926 separation method Methods 0.000 description 3
238000001356 surgical procedure Methods 0.000 description 3
230000017423 tissue regeneration Effects 0.000 description 3
210000000515 tooth Anatomy 0.000 description 3
RFLVMTUMFYRZCB-UHFFFAOYSA-N 1-methylguanine Chemical compound O=C1N(C)C(N)=NC2=C1N=CN2 RFLVMTUMFYRZCB-UHFFFAOYSA-N 0.000 description 2
YSAJFXWTVFGPAX-UHFFFAOYSA-N 2-[(2,4-dioxo-1h-pyrimidin-5-yl)oxy]acetic acid Chemical compound OC(=O)COC1=CNC(=O)NC1=O YSAJFXWTVFGPAX-UHFFFAOYSA-N 0.000 description 2
FZWGECJQACGGTI-UHFFFAOYSA-N 2-amino-7-methyl-1,7-dihydro-6H-purin-6-one Chemical compound NC1=NC(O)=C2N(C)C=NC2=N1 FZWGECJQACGGTI-UHFFFAOYSA-N 0.000 description 2
OVONXEQGWXGFJD-UHFFFAOYSA-N 4-sulfanylidene-1h-pyrimidin-2-one Chemical compound SC=1C=CNC(=O)N=1 OVONXEQGWXGFJD-UHFFFAOYSA-N 0.000 description 2
OIVLITBTBDPEFK-UHFFFAOYSA-N 5,6-dihydrouracil Chemical compound O=C1CCNC(=O)N1 OIVLITBTBDPEFK-UHFFFAOYSA-N 0.000 description 2
LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
240000001592 Amaranthus caudatus Species 0.000 description 2
235000009328 Amaranthus caudatus Nutrition 0.000 description 2
108020005544 Antisense RNA Proteins 0.000 description 2
BHELIUBJHYAEDK-OAIUPTLZSA-N Aspoxicillin Chemical compound C1([C@H](C(=O)N[C@@H]2C(N3[C@H](C(C)(C)S[C@@H]32)C(O)=O)=O)NC(=O)[C@H](N)CC(=O)NC)=CC=C(O)C=C1 BHELIUBJHYAEDK-OAIUPTLZSA-N 0.000 description 2
101150013907 BHLH gene Proteins 0.000 description 2
241000212384 Bifora Species 0.000 description 2
241000283690 Bos taurus Species 0.000 description 2
108091003079 Bovine Serum Albumin Proteins 0.000 description 2
241000282472 Canis lupus familiaris Species 0.000 description 2
241000283707 Capra Species 0.000 description 2
108700007800 Drosophila N Proteins 0.000 description 2
238000002965 ELISA Methods 0.000 description 2
241000283086 Equidae Species 0.000 description 2
241000282326 Felis catus Species 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 2
101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 2
101000978766 Homo sapiens Neurogenic locus notch homolog protein 1 Proteins 0.000 description 2
102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 2
108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 2
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
HYVABZIGRDEKCD-UHFFFAOYSA-N N(6)-dimethylallyladenine Chemical compound CC(C)=CCNC1=NC=NC2=C1N=CN2 HYVABZIGRDEKCD-UHFFFAOYSA-N 0.000 description 2
241000244206 Nematoda Species 0.000 description 2
108700037064 Neurogenic locus notch homolog protein 2 Proteins 0.000 description 2
102100025246 Neurogenic locus notch homolog protein 2 Human genes 0.000 description 2
102000007999 Nuclear Proteins Human genes 0.000 description 2
108010089610 Nuclear Proteins Proteins 0.000 description 2
108091028043 Nucleic acid sequence Proteins 0.000 description 2
241000283973 Oryctolagus cuniculus Species 0.000 description 2
241000237988 Patellidae Species 0.000 description 2
RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
108020004511 Recombinant DNA Proteins 0.000 description 2
108700008625 Reporter Genes Proteins 0.000 description 2
240000004808 Saccharomyces cerevisiae Species 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
241000282887 Suidae Species 0.000 description 2
108050003627 Wnt Proteins 0.000 description 2
102000013814 Wnt Human genes 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 2
APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 2
238000010171 animal model Methods 0.000 description 2
230000003042 antagnostic effect Effects 0.000 description 2
210000003719 b-lymphocyte Anatomy 0.000 description 2
210000002469 basement membrane Anatomy 0.000 description 2
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
238000001815 biotherapy Methods 0.000 description 2
230000000903 blocking effect Effects 0.000 description 2
230000033081 cell fate specification Effects 0.000 description 2
210000001638 cerebellum Anatomy 0.000 description 2
230000008859 change Effects 0.000 description 2
238000002512 chemotherapy Methods 0.000 description 2
210000000349 chromosome Anatomy 0.000 description 2
238000003776 cleavage reaction Methods 0.000 description 2
230000000295 complement effect Effects 0.000 description 2
230000006378 damage Effects 0.000 description 2
238000012217 deletion Methods 0.000 description 2
230000037430 deletion Effects 0.000 description 2
210000004207 dermis Anatomy 0.000 description 2
238000001514 detection method Methods 0.000 description 2
238000009826 distribution Methods 0.000 description 2
229960003638 dopamine Drugs 0.000 description 2
238000012137 double-staining Methods 0.000 description 2
210000004670 early embryonic cell Anatomy 0.000 description 2
235000013399 edible fruits Nutrition 0.000 description 2
238000004520 electroporation Methods 0.000 description 2
210000002253 embryonic cardiomyocyte Anatomy 0.000 description 2
239000000839 emulsion Substances 0.000 description 2
239000012091 fetal bovine serum Substances 0.000 description 2
238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
210000001156 gastric mucosa Anatomy 0.000 description 2
238000012252 genetic analysis Methods 0.000 description 2
210000004907 gland Anatomy 0.000 description 2
239000011521 glass Substances 0.000 description 2
230000002518 glial effect Effects 0.000 description 2
230000006266 hibernation Effects 0.000 description 2
229940088597 hormone Drugs 0.000 description 2
239000005556 hormone Substances 0.000 description 2
102000045609 human NOTCH1 Human genes 0.000 description 2
238000009396 hybridization Methods 0.000 description 2
230000028993 immune response Effects 0.000 description 2
238000002649 immunization Methods 0.000 description 2
230000003053 immunization Effects 0.000 description 2
239000000411 inducer Substances 0.000 description 2
238000001802 infusion Methods 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
208000014674 injury Diseases 0.000 description 2
229910052500 inorganic mineral Inorganic materials 0.000 description 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
238000007914 intraventricular administration Methods 0.000 description 2
210000002510 keratinocyte Anatomy 0.000 description 2
210000003734 kidney Anatomy 0.000 description 2
108020001756 ligand binding domains Proteins 0.000 description 2
230000000670 limiting effect Effects 0.000 description 2
210000004698 lymphocyte Anatomy 0.000 description 2
210000004962 mammalian cell Anatomy 0.000 description 2
239000003550 marker Substances 0.000 description 2
239000000463 material Substances 0.000 description 2
230000037306 mature skin Effects 0.000 description 2
238000002844 melting Methods 0.000 description 2
230000008018 melting Effects 0.000 description 2
YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical compound CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 description 2
239000011707 mineral Substances 0.000 description 2
235000010755 mineral Nutrition 0.000 description 2
230000000877 morphologic effect Effects 0.000 description 2
229940126619 mouse monoclonal antibody Drugs 0.000 description 2
210000003205 muscle Anatomy 0.000 description 2
230000004766 neurogenesis Effects 0.000 description 2
230000004031 neuronal differentiation Effects 0.000 description 2
230000003287 optical effect Effects 0.000 description 2
230000005305 organ development Effects 0.000 description 2
230000002018 overexpression Effects 0.000 description 2
210000000496 pancreas Anatomy 0.000 description 2
229940056360 penicillin g Drugs 0.000 description 2
210000003800 pharynx Anatomy 0.000 description 2
210000000608 photoreceptor cell Anatomy 0.000 description 2
108091008695 photoreceptors Proteins 0.000 description 2
230000010399 physical interaction Effects 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
238000012545 processing Methods 0.000 description 2
230000002685 pulmonary effect Effects 0.000 description 2
KIDHWZJUCRJVML-UHFFFAOYSA-N putrescine Chemical compound NCCCCN KIDHWZJUCRJVML-UHFFFAOYSA-N 0.000 description 2
230000005855 radiation Effects 0.000 description 2
230000007115 recruitment Effects 0.000 description 2
230000008439 repair process Effects 0.000 description 2
230000003252 repetitive effect Effects 0.000 description 2
210000002345 respiratory system Anatomy 0.000 description 2
230000008458 response to injury Effects 0.000 description 2
210000000964 retinal cone photoreceptor cell Anatomy 0.000 description 2
DWZAJFZEYZIHPO-UHFFFAOYSA-N santin Chemical compound C1=CC(OC)=CC=C1C1=C(OC)C(=O)C2=C(O)C(OC)=C(O)C=C2O1 DWZAJFZEYZIHPO-UHFFFAOYSA-N 0.000 description 2
230000007017 scission Effects 0.000 description 2
230000007781 signaling event Effects 0.000 description 2
210000004927 skin cell Anatomy 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
239000007787 solid Substances 0.000 description 2
230000000392 somatic effect Effects 0.000 description 2
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
210000001685 thyroid gland Anatomy 0.000 description 2
210000003014 totipotent stem cell Anatomy 0.000 description 2
238000010361 transduction Methods 0.000 description 2
230000026683 transduction Effects 0.000 description 2
238000001890 transfection Methods 0.000 description 2
230000010474 transient expression Effects 0.000 description 2
230000032258 transport Effects 0.000 description 2
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
241001430294 unidentified retrovirus Species 0.000 description 2
229940035893 uracil Drugs 0.000 description 2
230000002620 ureteric effect Effects 0.000 description 2
230000003612 virological effect Effects 0.000 description 2
DFUSDJMZWQVQSF-XLGIIRLISA-N (2r)-2-methyl-2-[(4r,8r)-4,8,12-trimethyltridecyl]-3,4-dihydrochromen-6-ol Chemical compound OC1=CC=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1 DFUSDJMZWQVQSF-XLGIIRLISA-N 0.000 description 1
CADQNXRGRFJSQY-UOWFLXDJSA-N (2r,3r,4r)-2-fluoro-2,3,4,5-tetrahydroxypentanal Chemical compound OC[C@@H](O)[C@@H](O)[C@@](O)(F)C=O CADQNXRGRFJSQY-UOWFLXDJSA-N 0.000 description 1
ASWBNKHCZGQVJV-UHFFFAOYSA-N (3-hexadecanoyloxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)COP([O-])(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-UHFFFAOYSA-N 0.000 description 1
102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
WJNGQIYEQLPJMN-IOSLPCCCSA-N 1-methylinosine Chemical compound C1=NC=2C(=O)N(C)C=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O WJNGQIYEQLPJMN-IOSLPCCCSA-N 0.000 description 1
UFBJCMHMOXMLKC-UHFFFAOYSA-N 2,4-dinitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O UFBJCMHMOXMLKC-UHFFFAOYSA-N 0.000 description 1
WEEMDRWIKYCTQM-UHFFFAOYSA-N 2,6-dimethoxybenzenecarbothioamide Chemical compound COC1=CC=CC(OC)=C1C(N)=S WEEMDRWIKYCTQM-UHFFFAOYSA-N 0.000 description 1
XMSMHKMPBNTBOD-UHFFFAOYSA-N 2-dimethylamino-6-hydroxypurine Chemical compound N1C(N(C)C)=NC(=O)C2=C1N=CN2 XMSMHKMPBNTBOD-UHFFFAOYSA-N 0.000 description 1
XBBVURRQGJPTHH-UHFFFAOYSA-N 2-hydroxyacetic acid;2-hydroxypropanoic acid Chemical compound OCC(O)=O.CC(O)C(O)=O XBBVURRQGJPTHH-UHFFFAOYSA-N 0.000 description 1
SMADWRYCYBUIKH-UHFFFAOYSA-N 2-methyl-7h-purin-6-amine Chemical compound CC1=NC(N)=C2NC=NC2=N1 SMADWRYCYBUIKH-UHFFFAOYSA-N 0.000 description 1
KOLPWZCZXAMXKS-UHFFFAOYSA-N 3-methylcytosine Chemical compound CN1C(N)=CC=NC1=O KOLPWZCZXAMXKS-UHFFFAOYSA-N 0.000 description 1
GJAKJCICANKRFD-UHFFFAOYSA-N 4-acetyl-4-amino-1,3-dihydropyrimidin-2-one Chemical compound CC(=O)C1(N)NC(=O)NC=C1 GJAKJCICANKRFD-UHFFFAOYSA-N 0.000 description 1
WPYRHVXCOQLYLY-UHFFFAOYSA-N 5-[(methoxyamino)methyl]-2-sulfanylidene-1h-pyrimidin-4-one Chemical compound CONCC1=CNC(=S)NC1=O WPYRHVXCOQLYLY-UHFFFAOYSA-N 0.000 description 1
LQLQRFGHAALLLE-UHFFFAOYSA-N 5-bromouracil Chemical compound BrC1=CNC(=O)NC1=O LQLQRFGHAALLLE-UHFFFAOYSA-N 0.000 description 1
ZFTBZKVVGZNMJR-UHFFFAOYSA-N 5-chlorouracil Chemical compound ClC1=CNC(=O)NC1=O ZFTBZKVVGZNMJR-UHFFFAOYSA-N 0.000 description 1
KSNXJLQDQOIRIP-UHFFFAOYSA-N 5-iodouracil Chemical compound IC1=CNC(=O)NC1=O KSNXJLQDQOIRIP-UHFFFAOYSA-N 0.000 description 1
ZLAQATDNGLKIEV-UHFFFAOYSA-N 5-methyl-2-sulfanylidene-1h-pyrimidin-4-one Chemical compound CC1=CNC(=S)NC1=O ZLAQATDNGLKIEV-UHFFFAOYSA-N 0.000 description 1
LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical compound CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 description 1
DCPSTSVLRXOYGS-UHFFFAOYSA-N 6-amino-1h-pyrimidine-2-thione Chemical compound NC1=CC=NC(S)=N1 DCPSTSVLRXOYGS-UHFFFAOYSA-N 0.000 description 1
MSSXOMSJDRHRMC-UHFFFAOYSA-N 9H-purine-2,6-diamine Chemical compound NC1=NC(N)=C2NC=NC2=N1 MSSXOMSJDRHRMC-UHFFFAOYSA-N 0.000 description 1
RSWGJHLUYNHPMX-UHFFFAOYSA-N Abietic-Saeure Natural products C12CCC(C(C)C)=CC2=CCC2C1(C)CCCC2(C)C(O)=O RSWGJHLUYNHPMX-UHFFFAOYSA-N 0.000 description 1
108700028369 Alleles Proteins 0.000 description 1
201000004384 Alopecia Diseases 0.000 description 1
241001156002 Anthonomus pomorum Species 0.000 description 1
241001351283 Arta Species 0.000 description 1
241000972773 Aulopiformes Species 0.000 description 1
241000271566 Aves Species 0.000 description 1
102000007350 Bone Morphogenetic Proteins Human genes 0.000 description 1
108010007726 Bone Morphogenetic Proteins Proteins 0.000 description 1
101100385401 Caenorhabditis elegans kin-10 gene Proteins 0.000 description 1
101100074828 Caenorhabditis elegans lin-12 gene Proteins 0.000 description 1
241000252229 Carassius auratus Species 0.000 description 1
108010078791 Carrier Proteins Proteins 0.000 description 1
108090000994 Catalytic RNA Proteins 0.000 description 1
102000053642 Catalytic RNA Human genes 0.000 description 1
241000581364 Clinitrachus argentatus Species 0.000 description 1
108020004394 Complementary RNA Proteins 0.000 description 1
241000186216 Corynebacterium Species 0.000 description 1
239000004971 Cross linker Substances 0.000 description 1
ZAQJHHRNXZUBTE-WUJLRWPWSA-N D-xylulose Chemical compound OC[C@@H](O)[C@H](O)C(=O)CO ZAQJHHRNXZUBTE-WUJLRWPWSA-N 0.000 description 1
102000053602 DNA Human genes 0.000 description 1
230000006820 DNA synthesis Effects 0.000 description 1
241000252212 Danio rerio Species 0.000 description 1
241000702421 Dependoparvovirus Species 0.000 description 1
101100121125 Drosophila melanogaster RasGAP1 gene Proteins 0.000 description 1
108700030338 Drosophila wg Proteins 0.000 description 1
206010058314 Dysplasia Diseases 0.000 description 1
229920003299 Eltex® Polymers 0.000 description 1
102000018898 GTPase-Activating Proteins Human genes 0.000 description 1
108091006094 GTPase-accelerating proteins Proteins 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
108700039691 Genetic Promoter Regions Proteins 0.000 description 1
238000006143 Gilbert reaction Methods 0.000 description 1
244000060234 Gmelina philippensis Species 0.000 description 1
101000577199 Homo sapiens Neurogenic locus notch homolog protein 2 Proteins 0.000 description 1
102000003839 Human Proteins Human genes 0.000 description 1
108090000144 Human Proteins Proteins 0.000 description 1
XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
206010061598 Immunodeficiency Diseases 0.000 description 1
102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
206010062016 Immunosuppression Diseases 0.000 description 1
UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
229930010555 Inosine Natural products 0.000 description 1
102000004877 Insulin Human genes 0.000 description 1
108090001061 Insulin Proteins 0.000 description 1
102000015696 Interleukins Human genes 0.000 description 1
108010063738 Interleukins Proteins 0.000 description 1
NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
101710189714 Major cell-binding factor Proteins 0.000 description 1
206010054949 Metaplasia Diseases 0.000 description 1
101100294417 Mus musculus Notch1 gene Proteins 0.000 description 1
101000809255 Mus musculus Ubiquitin carboxyl-terminal hydrolase 4 Proteins 0.000 description 1
101100156757 Mus musculus Wnt1 gene Proteins 0.000 description 1
SGSSKEDGVONRGC-UHFFFAOYSA-N N(2)-methylguanine Chemical compound O=C1NC(NC)=NC2=C1N=CN2 SGSSKEDGVONRGC-UHFFFAOYSA-N 0.000 description 1
244000183278 Nephelium litchi Species 0.000 description 1
101100247316 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) ras-1 gene Proteins 0.000 description 1
102000019040 Nuclear Antigens Human genes 0.000 description 1
108010051791 Nuclear Antigens Proteins 0.000 description 1
239000012124 Opti-MEM Substances 0.000 description 1
102000016979 Other receptors Human genes 0.000 description 1
229930182555 Penicillin Natural products 0.000 description 1
102000057297 Pepsin A Human genes 0.000 description 1
108090000284 Pepsin A Proteins 0.000 description 1
OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical group [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
108091000080 Phosphotransferase Proteins 0.000 description 1
241000276498 Pollachius virens Species 0.000 description 1
208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
244000028344 Primula vulgaris Species 0.000 description 1
235000016311 Primula vulgaris Nutrition 0.000 description 1
102000001253 Protein Kinase Human genes 0.000 description 1
201000004681 Psoriasis Diseases 0.000 description 1
239000005700 Putrescine Substances 0.000 description 1
102100030000 Recombining binding protein suppressor of hairless Human genes 0.000 description 1
108091028664 Ribonucleotide Proteins 0.000 description 1
KHPCPRHQVVSZAH-HUOMCSJISA-N Rosin Natural products O(C/C=C/c1ccccc1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 KHPCPRHQVVSZAH-HUOMCSJISA-N 0.000 description 1
241000714474 Rous sarcoma virus Species 0.000 description 1
102000005588 Son of Sevenless Proteins Human genes 0.000 description 1
108010059447 Son of Sevenless Proteins Proteins 0.000 description 1
101710088944 Suppressor of hairless protein Proteins 0.000 description 1
208000000389 T-cell leukemia Diseases 0.000 description 1
208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 description 1
210000000173 T-lymphoid precursor cell Anatomy 0.000 description 1
102000036693 Thrombopoietin Human genes 0.000 description 1
108010041111 Thrombopoietin Proteins 0.000 description 1
102000006601 Thymidine Kinase Human genes 0.000 description 1
108020004440 Thymidine kinase Proteins 0.000 description 1
102000004338 Transferrin Human genes 0.000 description 1
108090000901 Transferrin Proteins 0.000 description 1
108700019146 Transgenes Proteins 0.000 description 1
208000036142 Viral infection Diseases 0.000 description 1
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
206010000210 abortion Diseases 0.000 description 1
231100000176 abortion Toxicity 0.000 description 1
239000012190 activator Substances 0.000 description 1
239000013543 active substance Substances 0.000 description 1
229960000643 adenine Drugs 0.000 description 1
208000009956 adenocarcinoma Diseases 0.000 description 1
230000001464 adherent effect Effects 0.000 description 1
239000000853 adhesive Substances 0.000 description 1
230000001070 adhesive effect Effects 0.000 description 1
210000001789 adipocyte Anatomy 0.000 description 1
210000001943 adrenal medulla Anatomy 0.000 description 1
125000000217 alkyl group Chemical group 0.000 description 1
230000004075 alteration Effects 0.000 description 1
WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
230000019552 anatomical structure morphogenesis Effects 0.000 description 1
210000004102 animal cell Anatomy 0.000 description 1
230000003466 anti-cipated effect Effects 0.000 description 1
230000006907 apoptotic process Effects 0.000 description 1
239000012062 aqueous buffer Substances 0.000 description 1
239000012298 atmosphere Substances 0.000 description 1
210000003050 axon Anatomy 0.000 description 1
230000003376 axonal effect Effects 0.000 description 1
239000013602 bacteriophage vector Substances 0.000 description 1
210000000270 basal cell Anatomy 0.000 description 1
230000006399 behavior Effects 0.000 description 1
230000003542 behavioural effect Effects 0.000 description 1
230000008901 benefit Effects 0.000 description 1
125000001488 beta-D-galactosyl group Chemical group C1([C@H](O)[C@@H](O)[C@@H](O)[C@H](O1)CO)* 0.000 description 1
230000008827 biological function Effects 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
230000008499 blood brain barrier function Effects 0.000 description 1
210000000601 blood cell Anatomy 0.000 description 1
210000001218 blood-brain barrier Anatomy 0.000 description 1
210000002449 bone cell Anatomy 0.000 description 1
210000004958 brain cell Anatomy 0.000 description 1
230000004641 brain development Effects 0.000 description 1
210000005013 brain tissue Anatomy 0.000 description 1
238000005282 brightening Methods 0.000 description 1
239000000872 buffer Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
239000000969 carrier Substances 0.000 description 1
230000003197 catalytic effect Effects 0.000 description 1
230000007348 cell dedifferentiation Effects 0.000 description 1
230000033026 cell fate determination Effects 0.000 description 1
230000007910 cell fusion Effects 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
239000013553 cell monolayer Substances 0.000 description 1
230000009087 cell motility Effects 0.000 description 1
230000003833 cell viability Effects 0.000 description 1
230000008614 cellular interaction Effects 0.000 description 1
230000036755 cellular response Effects 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
230000002490 cerebral effect Effects 0.000 description 1
210000004289 cerebral ventricle Anatomy 0.000 description 1
210000003679 cervix uteri Anatomy 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
239000003638 chemical reducing agent Substances 0.000 description 1
230000008045 co-localization Effects 0.000 description 1
210000001072 colon Anatomy 0.000 description 1
238000010293 colony formation assay Methods 0.000 description 1
239000002299 complementary DNA Substances 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
239000012141 concentrate Substances 0.000 description 1
238000009833 condensation Methods 0.000 description 1
230000005494 condensation Effects 0.000 description 1
210000002808 connective tissue Anatomy 0.000 description 1
230000006552 constitutive activation Effects 0.000 description 1
230000001276 controlling effect Effects 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
210000004748 cultured cell Anatomy 0.000 description 1
125000004122 cyclic group Chemical group 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000032459 dedifferentiation Effects 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
238000000432 density-gradient centrifugation Methods 0.000 description 1
238000009795 derivation Methods 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
230000001079 digestive effect Effects 0.000 description 1
RJBIAAZJODIFHR-UHFFFAOYSA-N dihydroxy-imino-sulfanyl-$l^{5}-phosphane Chemical compound NP(O)(O)=S RJBIAAZJODIFHR-UHFFFAOYSA-N 0.000 description 1
238000007865 diluting Methods 0.000 description 1
BVTBRVFYZUCAKH-UHFFFAOYSA-L disodium selenite Chemical compound [Na+].[Na+].[O-][Se]([O-])=O BVTBRVFYZUCAKH-UHFFFAOYSA-L 0.000 description 1
238000010494 dissociation reaction Methods 0.000 description 1
230000005593 dissociations Effects 0.000 description 1
230000003291 dopaminomimetic effect Effects 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
230000007783 downstream signaling Effects 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
230000009977 dual effect Effects 0.000 description 1
239000012636 effector Substances 0.000 description 1
235000013601 eggs Nutrition 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
210000003038 endothelium Anatomy 0.000 description 1
230000008472 epithelial growth Effects 0.000 description 1
238000004299 exfoliation Methods 0.000 description 1
210000002744 extracellular matrix Anatomy 0.000 description 1
210000000744 eyelid Anatomy 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
239000000835 fiber Substances 0.000 description 1
MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
210000001061 forehead Anatomy 0.000 description 1
238000009472 formulation Methods 0.000 description 1
238000005194 fractionation Methods 0.000 description 1
230000004927 fusion Effects 0.000 description 1
108020001507 fusion proteins Proteins 0.000 description 1
102000037865 fusion proteins Human genes 0.000 description 1
210000000232 gallbladder Anatomy 0.000 description 1
239000000499 gel Substances 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
210000004602 germ cell Anatomy 0.000 description 1
239000008103 glucose Substances 0.000 description 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
230000003394 haemopoietic effect Effects 0.000 description 1
230000003676 hair loss Effects 0.000 description 1
238000003306 harvesting Methods 0.000 description 1
210000003128 head Anatomy 0.000 description 1
230000036541 health Effects 0.000 description 1
210000002064 heart cell Anatomy 0.000 description 1
108060003552 hemocyanin Proteins 0.000 description 1
210000003897 hepatic stem cell Anatomy 0.000 description 1
150000002402 hexoses Chemical class 0.000 description 1
210000001320 hippocampus Anatomy 0.000 description 1
230000006801 homologous recombination Effects 0.000 description 1
238000002744 homologous recombination Methods 0.000 description 1
102000046883 human NOTCH2 Human genes 0.000 description 1
229910052588 hydroxylapatite Inorganic materials 0.000 description 1
210000002865 immune cell Anatomy 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
238000012760 immunocytochemical staining Methods 0.000 description 1
238000010166 immunofluorescence Methods 0.000 description 1
230000016784 immunoglobulin production Effects 0.000 description 1
238000003364 immunohistochemistry Methods 0.000 description 1
230000001506 immunosuppresive effect Effects 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
238000002513 implantation Methods 0.000 description 1
230000008676 import Effects 0.000 description 1
230000001976 improved effect Effects 0.000 description 1
238000000099 in vitro assay Methods 0.000 description 1
238000012750 in vivo screening Methods 0.000 description 1
230000002779 inactivation Effects 0.000 description 1
238000011534 incubation Methods 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
229960003786 inosine Drugs 0.000 description 1
229940125396 insulin Drugs 0.000 description 1
230000010354 integration Effects 0.000 description 1
230000035990 intercellular signaling Effects 0.000 description 1
210000004347 intestinal mucosa Anatomy 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
238000007913 intrathecal administration Methods 0.000 description 1
230000009545 invasion Effects 0.000 description 1
230000000155 isotopic effect Effects 0.000 description 1
231100000518 lethal Toxicity 0.000 description 1
230000001665 lethal effect Effects 0.000 description 1
229960004194 lidocaine Drugs 0.000 description 1
238000001638 lipofection Methods 0.000 description 1
239000002502 liposome Substances 0.000 description 1
239000006193 liquid solution Substances 0.000 description 1
239000006194 liquid suspension Substances 0.000 description 1
239000003589 local anesthetic agent Substances 0.000 description 1
230000004807 localization Effects 0.000 description 1
208000003747 lymphoid leukemia Diseases 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
230000035800 maturation Effects 0.000 description 1
238000005259 measurement Methods 0.000 description 1
210000002418 meninge Anatomy 0.000 description 1
210000001259 mesencephalon Anatomy 0.000 description 1
230000015689 metaplastic ossification Effects 0.000 description 1
150000004702 methyl esters Chemical class 0.000 description 1
238000000520 microinjection Methods 0.000 description 1
239000003607 modifier Substances 0.000 description 1
238000007479 molecular analysis Methods 0.000 description 1
230000001002 morphogenetic effect Effects 0.000 description 1
210000002200 mouth mucosa Anatomy 0.000 description 1
XJVXMWNLQRTRGH-UHFFFAOYSA-N n-(3-methylbut-3-enyl)-2-methylsulfanyl-7h-purin-6-amine Chemical compound CSC1=NC(NCCC(C)=C)=C2NC=NC2=N1 XJVXMWNLQRTRGH-UHFFFAOYSA-N 0.000 description 1
239000013642 negative control Substances 0.000 description 1
230000001613 neoplastic effect Effects 0.000 description 1
210000001577 neostriatum Anatomy 0.000 description 1
210000000933 neural crest Anatomy 0.000 description 1
210000003757 neuroblast Anatomy 0.000 description 1
230000004770 neurodegeneration Effects 0.000 description 1
208000015122 neurodegenerative disease Diseases 0.000 description 1
HIXQCPGXQVQHJP-UHFFFAOYSA-N nobin Chemical compound C1=CC=C2C(C3=C4C=CC=CC4=CC=C3N)=C(O)C=CC2=C1 HIXQCPGXQVQHJP-UHFFFAOYSA-N 0.000 description 1
210000003458 notochord Anatomy 0.000 description 1
230000005937 nuclear translocation Effects 0.000 description 1
238000011580 nude mouse model Methods 0.000 description 1
231100000590 oncogenic Toxicity 0.000 description 1
230000002246 oncogenic effect Effects 0.000 description 1
238000011275 oncology therapy Methods 0.000 description 1
230000005868 ontogenesis Effects 0.000 description 1
210000000287 oocyte Anatomy 0.000 description 1
230000002188 osteogenic effect Effects 0.000 description 1
230000002138 osteoinductive effect Effects 0.000 description 1
230000002611 ovarian Effects 0.000 description 1
238000012261 overproduction Methods 0.000 description 1
238000004806 packaging method and process Methods 0.000 description 1
210000002741 palatine tonsil Anatomy 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
230000007170 pathology Effects 0.000 description 1
229940049954 penicillin Drugs 0.000 description 1
XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
229940111202 pepsin Drugs 0.000 description 1
230000002085 persistent effect Effects 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
PTMHPRAIXMAOOB-UHFFFAOYSA-L phosphoramidate Chemical compound NP([O-])([O-])=O PTMHPRAIXMAOOB-UHFFFAOYSA-L 0.000 description 1
102000020233 phosphotransferase Human genes 0.000 description 1
230000035790 physiological processes and functions Effects 0.000 description 1
210000004694 pigment cell Anatomy 0.000 description 1
239000013612 plasmid Substances 0.000 description 1
239000004033 plastic Substances 0.000 description 1
238000007747 plating Methods 0.000 description 1
210000001778 pluripotent stem cell Anatomy 0.000 description 1
229920001983 poloxamer Polymers 0.000 description 1
229920000447 polyanionic polymer Polymers 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
229920005862 polyol Polymers 0.000 description 1
150000003077 polyols Chemical class 0.000 description 1
210000002975 pon Anatomy 0.000 description 1
239000011148 porous material Substances 0.000 description 1
230000035409 positive regulation of cell proliferation Effects 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
230000035935 pregnancy Effects 0.000 description 1
239000000186 progesterone Substances 0.000 description 1
229960003387 progesterone Drugs 0.000 description 1
230000002250 progressing effect Effects 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
238000000159 protein binding assay Methods 0.000 description 1
235000004252 protein component Nutrition 0.000 description 1
108020001580 protein domains Proteins 0.000 description 1
108060006633 protein kinase Proteins 0.000 description 1
230000004850 protein–protein interaction Effects 0.000 description 1
238000000746 purification Methods 0.000 description 1
238000001959 radiotherapy Methods 0.000 description 1
230000009257 reactivity Effects 0.000 description 1
230000000384 rearing effect Effects 0.000 description 1
238000003259 recombinant expression Methods 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
230000001172 regenerating effect Effects 0.000 description 1
238000007634 remodeling Methods 0.000 description 1
230000010076 replication Effects 0.000 description 1
230000000241 respiratory effect Effects 0.000 description 1
230000029058 respiratory gaseous exchange Effects 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
239000002336 ribonucleotide Substances 0.000 description 1
108091092562 ribozyme Proteins 0.000 description 1
235000019515 salmon Nutrition 0.000 description 1
239000004576 sand Substances 0.000 description 1
238000012216 screening Methods 0.000 description 1
230000028327 secretion Effects 0.000 description 1
238000005204 segregation Methods 0.000 description 1
230000001953 sensory effect Effects 0.000 description 1
239000012679 serum free medium Substances 0.000 description 1
230000001568 sexual effect Effects 0.000 description 1
230000035939 shock Effects 0.000 description 1
238000007873 sieving Methods 0.000 description 1
230000008054 signal transmission Effects 0.000 description 1
230000007727 signaling mechanism Effects 0.000 description 1
150000003384 small molecules Chemical class 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229960001471 sodium selenite Drugs 0.000 description 1
239000011781 sodium selenite Substances 0.000 description 1
235000015921 sodium selenite Nutrition 0.000 description 1
239000007790 solid phase Substances 0.000 description 1
239000000243 solution Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
210000002023 somite Anatomy 0.000 description 1
230000009870 specific binding Effects 0.000 description 1
210000000952 spleen Anatomy 0.000 description 1
210000004989 spleen cell Anatomy 0.000 description 1
230000002269 spontaneous effect Effects 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
229960005322 streptomycin Drugs 0.000 description 1
229960002385 streptomycin sulfate Drugs 0.000 description 1
230000004960 subcellular localization Effects 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
125000001424 substituent group Chemical group 0.000 description 1
239000013589 supplement Substances 0.000 description 1
230000008093 supporting effect Effects 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
210000000106 sweat gland Anatomy 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
230000009897 systematic effect Effects 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
210000001550 testis Anatomy 0.000 description 1
101150026344 thy gene Proteins 0.000 description 1
210000001541 thymus gland Anatomy 0.000 description 1
KHPCPRHQVVSZAH-UHFFFAOYSA-N trans-cinnamyl beta-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OCC=CC1=CC=CC=C1 KHPCPRHQVVSZAH-UHFFFAOYSA-N 0.000 description 1
230000002103 transcriptional effect Effects 0.000 description 1
230000002463 transducing effect Effects 0.000 description 1
239000012581 transferrin Substances 0.000 description 1
230000009466 transformation Effects 0.000 description 1
230000001052 transient effect Effects 0.000 description 1
230000007704 transition Effects 0.000 description 1
238000013519 translation Methods 0.000 description 1
102000027257 transmembrane receptors Human genes 0.000 description 1
108091008578 transmembrane receptors Proteins 0.000 description 1
210000005239 tubule Anatomy 0.000 description 1
238000010396 two-hybrid screening Methods 0.000 description 1
238000011144 upstream manufacturing Methods 0.000 description 1
210000002700 urine Anatomy 0.000 description 1
210000002229 urogenital system Anatomy 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
210000005172 vertebrate brain Anatomy 0.000 description 1
230000035899 viability Effects 0.000 description 1
230000009385 viral infection Effects 0.000 description 1
210000002845 virion Anatomy 0.000 description 1
210000001835 viscera Anatomy 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
229940075420 xanthine Drugs 0.000 description 1
238000001086 yeast two-hybrid system Methods 0.000 description 1
239000011701 zinc Substances 0.000 description 1
229910052725 zinc Inorganic materials 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0618—Cells of the nervous system
- C12N5/0623—Stem cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0018—Culture media for cell or tissue culture
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0601—Invertebrate cells or tissues, e.g. insect cells; Culture media therefor
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/40—Regulators of development
- C12N2501/42—Notch; Delta; Jagged; Serrate

Landscapes

Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Life Sciences & Earth Sciences (AREA)
Biomedical Technology (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Zoology (AREA)
Biotechnology (AREA)
Genetics & Genomics (AREA)
Bioinformatics & Cheminformatics (AREA)
Wood Science & Technology (AREA)
General Health & Medical Sciences (AREA)
Biochemistry (AREA)
General Engineering & Computer Science (AREA)
Cell Biology (AREA)
Microbiology (AREA)
Medicinal Chemistry (AREA)
Biophysics (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Molecular Biology (AREA)
Developmental Biology & Embryology (AREA)
Toxicology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

JP09513747A 1995-09-29 1996-09-27 ノッチ経路を用いる最終未分化細胞の操作 Withdrawn JP2000511043A (ja)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US537,210		1995-09-29
US08/537,210 US5780300A (en)	1995-09-29	1995-09-29	Manipulation of non-terminally differentiated cells using the notch pathway
PCT/US1996/015651 WO1997011716A1 (en)	1995-09-29	1996-09-27	Manipulation of non-terminally differentiated cells using the notch pathway

Related Child Applications (1)

Application Number	Title	Priority Date	Filing Date
JP2009001970A Division JP2009143934A (ja)	1995-09-29	2009-01-07	ノッチ経路を用いる最終未分化細胞の操作

Publications (2)

Publication Number	Publication Date
JP2000511043A true JP2000511043A (ja)	2000-08-29
JP2000511043A5 JP2000511043A5 (2)	2004-09-30

Family

ID=24141687

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
JP09513747A Withdrawn JP2000511043A (ja)	1995-09-29	1996-09-27	ノッチ経路を用いる最終未分化細胞の操作
JP2009001970A Pending JP2009143934A (ja)	1995-09-29	2009-01-07	ノッチ経路を用いる最終未分化細胞の操作

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
JP2009001970A Pending JP2009143934A (ja)	1995-09-29	2009-01-07	ノッチ経路を用いる最終未分化細胞の操作

Country Status (6)

Country	Link
US (4)	US5780300A (2)
EP (1)	EP0948348B1 (2)
JP (2)	JP2000511043A (2)
AU (1)	AU732629B2 (2)
CA (1)	CA2233534C (2)
WO (1)	WO1997011716A1 (2)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2015004762A1 (ja) *	2013-07-10	2015-01-15	株式会社日立製作所	細胞培養方法、装置、及び細胞シート
JP2018506293A (ja) *	2015-02-24	2018-03-08	ザリージェンツオブザユニバーシティオブカリフォルニア	結合誘発型転写スイッチ及びその使用方法
JP2020072694A (ja) *	2014-06-04	2020-05-14	フレッドハッチンソンキャンサーリサーチセンター	Ｎｏｔｃｈ１および／またはＮｏｔｃｈ２アゴニストを用いた幹細胞の増殖および生着

Families Citing this family (121)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5786158A (en) *	1992-04-30	1998-07-28	Yale University	Therapeutic and diagnostic methods and compositions based on notch proteins and nucleic acids
US20050112121A1 (en) *	1992-04-30	2005-05-26	Yale University	Therapeutic and diagnostic methods and compositions based on notch proteins and nucleic acids
US20030225019A1 (en) *	2002-05-30	2003-12-04	Freier Susan M.	Notch1 inhibitors for inducing apoptosis
EP0861261B9 (en) *	1995-06-28	2010-02-24	Imperial Cancer Research Technology Limited	Nucleotide and protein sequences of vertebrate delta genes and methods based thereon
US20050158859A1 (en) *	1995-09-29	2005-07-21	Yale University	Manipulation of non-terminally differentiated cells using the Notch pathway
US5780300A (en) *	1995-09-29	1998-07-14	Yale University	Manipulation of non-terminally differentiated cells using the notch pathway
HUP9904567A3 (en)	1996-06-20	2001-10-29	Univ Texas	Use of azo, thioalkyl, thiocarbonyl derivatives substituted by fused heterocycles and/or phenyl group for the preparation of pharmaceutical compositions stimulating bone growth
CZ295997B6 (cs) *	1996-11-07	2005-12-14	Lorantis Limited	Farmaceutický prostředek s obsahem ligandu Notch a způsob tvorby T-buněk
US6887475B1 (en)	1996-11-07	2005-05-03	Lorantis Limited	Notch
US20060122373A1 (en) *	1997-04-04	2006-06-08	Millennium Pharmaceuticals, Inc.	Delta3, FTHMA-070, Tango85, Tango77, SPOIL,NEOKINE, Tango129 and integrin alpha subunit protein and nucleic acid molecules and uses thereof
US6121045A (en) *	1997-04-04	2000-09-19	Millennium Biotherapeutics, Inc.	Human Delta3 nucleic acid molecules
US6136952A (en)	1997-06-25	2000-10-24	University Of Washington	Human jagged polypeptide, encoding nucleic acids and methods of use
US6692919B1 (en)	1997-07-23	2004-02-17	Yale University	Activated forms of notch and methods based thereon
US6436650B1 (en)	1997-07-23	2002-08-20	Yale University	Activated forms of notch and methods based thereon
SE9802264D0 (sv)	1998-06-25	1998-06-25	Neuronova Ab	A method of isolating cells
US6541247B1 (en)	1998-06-25	2003-04-01	Neuronova Ab	Method of isolating ependymal neural stem cells
AU768269B2 (en) *	1998-10-02	2003-12-04	Government of The United States of America, as represented by The Secretary Department of Health & Human Services, The National Institutes of Health, The	Apoptosis inducing agents and methods
GB9824045D0 (en) *	1998-11-03	1998-12-30	European Molecular Biology Lab Embl	Regulator protein
WO2001003743A1 (en) *	1999-07-12	2001-01-18	Walter Gehring	Manipulation of tissue or organ type using the notch pathway
US8084258B2 (en)	1999-07-12	2011-12-27	University Of Basel	Manipulation of tissue of organ type using the notch pathway
US6720173B1 (en)	1999-11-08	2004-04-13	Lexicon Genetics Incorporated	Human kinase protein and polynucleotides encoding the same
US7575921B2 (en) *	1999-12-30	2009-08-18	Vbi Technologies, L.L.C.	Spore-like cells and uses thereof
US7560275B2 (en) *	1999-12-30	2009-07-14	Vbi Technologies, L.L.C.	Compositions and methods for generating skin
WO2001053503A1 (en) *	2000-01-18	2001-07-26	Cornell Research Foundation, Inc.	Neural progenitor cells from hippocampal tissue and a method for isolating and purifying them
US7037493B2 (en)	2000-05-01	2006-05-02	Cornell Research Foundation, Inc.	Method of inducing neuronal production in the brain and spinal cord
US7303769B2 (en) *	2000-06-05	2007-12-04	University Of South Florida	Method for purifying pluri-differentiated mesenchymal progenitor cells
US7442390B2 (en) *	2000-06-05	2008-10-28	University Of South Florida	Method for enhancing engraftment of cells using mesenchymal progenitor cells
US6936281B2 (en) *	2001-03-21	2005-08-30	University Of South Florida	Human mesenchymal progenitor cell
WO2001094541A2 (en) *	2000-06-05	2001-12-13	University Of South Florida	Human mesenchymal progenitor cell
US6984522B2 (en) *	2000-08-03	2006-01-10	Regents Of The University Of Michigan	Isolation and use of solid tumor stem cells
US8044259B2 (en)	2000-08-03	2011-10-25	The Regents Of The University Of Michigan	Determining the capability of a test compound to affect solid tumor stem cells
GB0019242D0 (en) *	2000-08-04	2000-09-27	Lorantis Ltd	Assay
AU2001284160A1 (en) *	2000-08-19	2002-03-04	Axordia Limited	Modulation of stem cell differentiation
AU2001288628A1 (en) *	2000-08-31	2002-03-13	Loyola University Chicago	Method and reagents for treatment of skin disorders by modulating the notch pathway
US7399633B2 (en) *	2000-10-27	2008-07-15	Fred Hutchinson Cancer Research Center	Methods for immortalizing cells
US20020151050A1 (en) *	2000-10-30	2002-10-17	Vacanti Charles A.	Isolation of spore-like cells from tissues exposed to extreme conditions
US6458588B1 (en)	2001-01-31	2002-10-01	The General Hospital Corporation	Renal stem cells and uses thereof
EP1383867A2 (en) *	2001-03-23	2004-01-28	Axordia Limited	Stem cell differentiation
WO2002078449A2 (en) *	2001-04-02	2002-10-10	Advanced Cell Technology, Inc.	Method for facilitating the production of differentiated cell types and tissues from embryonic and adult pluripotent and multipotent cells
CN1513148A (zh) *	2001-05-29	2004-07-14	��µ��ҵ��ʽ��	烹调实绩管理方法、内容管理方法、服务器和烹调设备
AU2002315337A1 (en) *	2001-06-18	2003-01-02	Psychiatric Genomics, Inc.	Method for neural stem cell differentiation using valproate
US7132287B2 (en) *	2001-06-18	2006-11-07	Psychiatric Genomics, Inc.	Method for neural stem cell differentiation using 5HT-1A agonists
US20050239064A1 (en) *	2001-06-18	2005-10-27	Spyridon Artavanis-Tsakonas	Methods and compositions based on protein interactions with mastermind
WO2003011317A1 (en) *	2001-07-25	2003-02-13	Lorantis Limited	Modulators of notch signalling for use in immunotherapy
US7452532B2 (en) *	2001-09-30	2008-11-18	Scicotec Gmbh	Transluminal application of adult stem cells for body organ tissue repair
US20030119080A1 (en) *	2001-10-15	2003-06-26	Mangano Joseph A.	Strategies for the identification and isolation of cancer stem cells and non-cancerous stem cells
CA2469204A1 (en) *	2001-12-07	2003-06-19	Regents Of The University Of Michigan	Prospective identification and characterization of breast cancer stem cells
DK1479767T3 (da) *	2002-02-06	2013-11-25	Sanbio Inc	Fremgangsmåde til differentiering/inducering af stromaceller fra knoglemarv til nerveceller ved overføring af Notch-gen
WO2003070189A2 (en) *	2002-02-15	2003-08-28	Cornell Research Foundation, Inc.	Enhancing neurotrophin-induced neurogenesis by endogenous neural progenitor cells by concurrent overexpression of brain derived neurotrophic factor and an inhibitor of a pro-gliogenic bone morphogenetic protein
US20050124572A1 (en) *	2002-06-17	2005-06-09	Freier Susan M.	Compositions and their uses directed to signal tranducers
US20040102390A1 (en) *	2002-11-21	2004-05-27	Isis Pharmaceuticals Inc.	Modulation of Notch3 expression
US20040101847A1 (en) *	2002-11-22	2004-05-27	Isis Pharmaceuticals Inc.	Modulation of Notch2 expression
US20040028661A1 (en) *	2002-08-07	2004-02-12	Bartelmez Stephen H.	Expansion of cells using thrombopoietin and anti-transforming growth factor-beta
EP1639090A4 (en) *	2003-06-09	2008-04-16	Univ Michigan	COMPOSITIONS AND METHODS OF TREATMENT AND DIAGNOSIS OF CANCER
US8029984B2 (en) *	2003-08-08	2011-10-04	Licentia, Ltd.	Materials and methods for colorectal cancer screening, diagnosis and therapy
US7897384B2 (en) *	2003-09-08	2011-03-01	Ethicon, Inc.	Chondrocyte therapeutic delivery system
US7927599B2 (en) *	2003-09-08	2011-04-19	Ethicon, Inc.	Chondrocyte therapeutic delivery system
US8257963B2 (en) *	2007-06-01	2012-09-04	Depuy Mitek, Inc.	Chondrocyte container and method of use
AU2005209909B8 (en) *	2004-02-03	2009-01-15	The Regents Of The University Of Michigan	Compositions and methods for characterizing, regulating, diagnosing, and treating cancer
US7837993B2 (en) *	2004-03-19	2010-11-23	The Board Of Trustees Of The Leland Stanford Junior University	Methods and compositions for regeneration of aged skeletal muscle tissues
PT1855700E (pt) *	2005-03-07	2013-12-10	Sanbio Inc	Utilização de materiais para tratamento de lesões do sistema nervoso central
US20060252073A1 (en) *	2005-04-18	2006-11-09	Regents Of The University Of Michigan	Compositions and methods for the treatment of cancer
EP1907858A4 (en) *	2005-06-13	2009-04-08	Univ Michigan	COMPOSITIONS AND METHODS OF TREATMENT AND DIAGNOSIS OF CANCER
WO2006135886A2 (en) *	2005-06-13	2006-12-21	The Regents Of The University Of Michigan	Compositions and methods for treating and diagnosing cancer
WO2007030693A2 (en) *	2005-09-08	2007-03-15	The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Methods for promoting stem cell proliferation and survival
JP5129149B2 (ja)	2005-10-31	2013-01-23	ザリージェンツオブザユニバーシティオブミシガン	癌を処置および診断するための組成物および方法
DK2500360T3 (en)	2005-10-31	2015-10-26	Oncomed Pharm Inc	Compositions and methods for the diagnosis and treatment of cancer
US7723477B2 (en)	2005-10-31	2010-05-25	Oncomed Pharmaceuticals, Inc.	Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
WO2008121102A2 (en) *	2006-02-21	2008-10-09	The Regents Of The University Of Michigan	Hedgehog signaling pathway antagonist cancer treatment
EP2081962B1 (en)	2006-10-19	2018-10-03	Genentech, Inc.	Novel anti-notch3 antibodies and their use in the detection and diagnosis of disease
AR063494A1 (es) *	2006-10-19	2009-01-28	Genentech Inc	Anticuerpos agonistas anti notch3 y su uso en el tratamiento de las enfermedades relacionadas con el gen notch3
JP5386364B2 (ja) *	2006-12-18	2014-01-15	ジェネンテック，インコーポレイテッド	抗Ｎｏｔｃｈ３アンタゴニスト抗体とＮｏｔｃｈ３関連疾患の予防及び治療におけるその使用
WO2008092002A2 (en)	2007-01-24	2008-07-31	The Regents Of The University Of Michigan	Compositions and methods for treating and diagnosing pancreatic cancer
PE20090321A1 (es)	2007-06-04	2009-04-20	Genentech Inc	Anticuerpos anti-notch1 nrr, metodo de preparacion y composicion farmaceutica
AU2008289209A1 (en) *	2007-08-16	2009-02-26	The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services	Methods for promoting stem cell proliferation and survival
CN103002911B (zh)	2008-09-26	2015-08-26	昂考梅德药品有限公司	卷曲蛋白结合药剂及其应用
PE20120080A1 (es) *	2008-10-01	2012-02-17	Genentech Inc	Anticuerpos anti-notch2 y metodos de uso
US20100125265A1 (en) *	2008-11-20	2010-05-20	Medtronic Vascular, Inc.	Cell Delivery System to Induce Cell Growth and Angiogenesis
JP2013510577A (ja)	2009-11-12	2013-03-28	ブイビーアイテクノロジーズ，エルエルシー	胞子様細胞の亜集団およびその用途
WO2011063237A2 (en)	2009-11-19	2011-05-26	Oncomed Pharmaceuticals, Inc.	Jagged-binding agents and uses thereof
TWI535445B (zh)	2010-01-12	2016-06-01	安可美德藥物股份有限公司	Ｗｎｔ拮抗劑及治療和篩選方法
CA2794674A1 (en)	2010-04-01	2011-10-06	Oncomed Pharmaceuticals, Inc.	Frizzled-binding agents and uses thereof
US20130095080A1 (en)	2010-04-09	2013-04-18	Fred Hutchinson Cancer Reserach Center	Compositions and methods for providing hematopoietic function
US20130095079A1 (en)	2010-04-09	2013-04-18	Fred Hutchinson Cancer Research Center	Compositions and methods for providing hematopoietic function without hla matching
EP2596119B8 (en)	2010-07-23	2021-06-02	Astellas Institute for Regenerative Medicine	Methods for detection of rare subpopulations of cells and highly purified compositions of cells
JP2011019520A (ja) *	2010-08-13	2011-02-03	Walter Gehring	Ｎｏｔｃｈ経路を用いた組織型または器官型の操作
EP2625264B1 (en)	2010-10-08	2022-12-07	Terumo BCT, Inc.	Methods and systems of growing and harvesting cells in a hollow fiber bioreactor system with control conditions
CA2858069C (en)	2011-12-08	2020-02-11	Novartis Ag	Compositions and methods for enhanced generation of hematopoietic stem/progenitor cells
WO2013188851A1 (en) *	2012-06-14	2013-12-19	Fred Hutchinson Cancer Research Center	Ex vivo expansion of myogenic stem cells by notch activation
WO2014066328A1 (en)	2012-10-23	2014-05-01	Oncomed Pharmaceuticals, Inc.	Methods of treating neuroendocrine tumors using wnt pathway-binding agents
EP2943566A1 (en)	2013-01-08	2015-11-18	Fred Hutchinson Cancer Research Center	Compositions and methods for expansion of embryonic hematopoietic stem cells
JP2016510411A (ja)	2013-02-04	2016-04-07	オンコメッドファーマシューティカルズインコーポレイテッド	Ｗｎｔ経路インヒビターによる処置の方法およびモニタリング
US9168300B2 (en)	2013-03-14	2015-10-27	Oncomed Pharmaceuticals, Inc.	MET-binding agents and uses thereof
MX389160B (es)	2013-10-31	2025-03-20	Hutchinson Fred Cancer Res	Células no t efectoras y madre/progenitoras hematopoyéticas modificadas y usos de estas.
JP6633522B2 (ja)	2013-11-16	2020-01-22	テルモビーシーティー、インコーポレーテッド	バイオリアクターにおける細胞増殖
WO2015148704A1 (en)	2014-03-25	2015-10-01	Terumo Bct, Inc.	Passive replacement of media
US20160090569A1 (en)	2014-09-26	2016-03-31	Terumo Bct, Inc.	Scheduled Feed
AU2016211671B2 (en)	2015-01-26	2022-05-26	Fate Therapeutics, Inc.	Methods and compositions for inducing hematopoietic cell differentiation
WO2016176651A2 (en)	2015-04-29	2016-11-03	Fred Hutchinson Cancer Research Center	Modified hematopoietic stem/progenitor and non-t effector cells, and uses thereof
EP3288570A4 (en)	2015-04-29	2018-11-21	Fred Hutchinson Cancer Research Center	Modified stem cells and uses thereof
WO2017004592A1 (en)	2015-07-02	2017-01-05	Terumo Bct, Inc.	Cell growth with mechanical stimuli
CA3003152A1 (en)	2015-11-04	2017-05-11	Fate Therapeutics, Inc.	Methods and compositions for inducing hematopoietic cell differentiation
JP6928604B2 (ja)	2015-11-04	2021-09-01	フェイトセラピューティクス，インコーポレイテッド	万能性細胞のゲノム改変
MX2018006828A (es)	2015-12-04	2018-08-09	Hutchinson Fred Cancer Res	Usos de poblaciones expandidas de celulas madre/progenitoras hematopoyeticas.
WO2017193059A1 (en)	2016-05-06	2017-11-09	The Regents Of The University Of California	Systems and methods for targeting cancer cells
JP7034949B2 (ja)	2016-05-25	2022-03-14	テルモビーシーティー、インコーポレーテッド	細胞の増殖
US11104874B2 (en)	2016-06-07	2021-08-31	Terumo Bct, Inc.	Coating a bioreactor
US11685883B2 (en)	2016-06-07	2023-06-27	Terumo Bct, Inc.	Methods and systems for coating a cell growth surface
JP7500195B2 (ja)	2016-08-23	2024-06-17	ザリージェンツオブザユニバーシティオブカリフォルニア	タンパク質分解により切断可能なキメラポリペプチド及びそれらの使用方法
US10767164B2 (en)	2017-03-30	2020-09-08	The Research Foundation For The State University Of New York	Microenvironments for self-assembly of islet organoids from stem cells differentiation
US11624046B2 (en)	2017-03-31	2023-04-11	Terumo Bct, Inc.	Cell expansion
CN117247899A (zh)	2017-03-31	2023-12-19	泰尔茂比司特公司	细胞扩增
US12234441B2 (en)	2017-03-31	2025-02-25	Terumo Bct, Inc.	Cell expansion
CN110055275A (zh) *	2018-01-19	2019-07-26	科济生物医药（上海）有限公司	一种质粒载体对、其修饰的免疫细胞及其应用
BR112021003830A2 (pt)	2018-08-28	2021-07-20	Fred Hutchinson Cancer Research Center	métodos e composições para terapia celular t adotiva incorporando sinalização notch induzida
EP3849565A4 (en)	2018-09-12	2022-12-28	Fred Hutchinson Cancer Research Center	REDUCTION OF CD33 EXPRESSION TO SELECTIVELY PROTECT THERAPEUTIC CELLS
GB2619893A (en)	2021-03-23	2023-12-20	Terumo Bct Inc	Cell capture and expansion
EP4476331A2 (en)	2022-02-07	2024-12-18	Ensoma, Inc.	Inhibitor-resistant mgmt modifications and modification of mgmt-encoding nucleic acids
US12152699B2 (en)	2022-02-28	2024-11-26	Terumo Bct, Inc.	Multiple-tube pinch valve assembly
CN115925925B (zh) *	2022-08-23	2024-02-06	江苏芯超生物科技(集团)有限公司	一种诱导脐带间充质干细胞分化并生产细胞因子的方法
USD1099116S1 (en)	2022-09-01	2025-10-21	Terumo Bct, Inc.	Display screen or portion thereof with a graphical user interface for displaying cell culture process steps and measurements of an associated bioreactor device

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5226914A (en) *	1990-11-16	1993-07-13	Caplan Arnold I	Method for treating connective tissue disorders
US5856441A (en) *	1991-05-03	1999-01-05	Yale University	Serrate fragments and derivatives
IE20030749A1 (en) *	1991-05-03	2003-11-12	Indiana University Foundation	Human notch and delta binding domains in torporythmic proteins, and methods based thereon
IL101728A (en) *	1991-05-03	2007-08-19	Univ Yale	Human Abandonment and Delta, Restrictive Areas of Effect in Tophoric Proteins, and Methods Based on Them
ES2198403T3 (es) *	1991-06-18	2004-02-01	Osiris Therapeutics, Inc.	Celulas madre mesenquimaticas humanas derivadas de medula y anticuerpos monoclonales especificos para dichas celulas.
US5869282A (en) *	1991-12-11	1999-02-09	Imperial Cancer Research Technology, Ltd.	Nucleotide and protein sequences of the serrate gene and methods based thereon
WO1993012141A1 (en) *	1991-12-11	1993-06-24	Yale University	Nucleotide and protein sequences of the serrate gene and methods based thereon
US6004924A (en) *	1991-12-11	1999-12-21	Imperial Cancer Research Technology, Ltd.	Protein sequences of serrate gene products
US5573905A (en) *	1992-03-30	1996-11-12	The Scripps Research Institute	Encoded combinatorial chemical libraries
US20050112121A1 (en) *	1992-04-30	2005-05-26	Yale University	Therapeutic and diagnostic methods and compositions based on notch proteins and nucleic acids
US5786158A (en) *	1992-04-30	1998-07-28	Yale University	Therapeutic and diagnostic methods and compositions based on notch proteins and nucleic acids
WO1994007522A1 (en) *	1992-09-30	1994-04-14	Yale University	Therapeutic and diagnostic methods and compositions based on transducin-like enhancer of split proteins and nucleic acids
WO1994008037A1 (en) *	1992-09-30	1994-04-14	Yale University	Human homologs of the transducin-like enhancer of split gene and methods based thereon
AU5669494A (en) *	1992-11-17	1994-06-08	Yale University	Human homolog of the e-cadherin gene and methods based thereon
PT673390E (pt) *	1992-12-11	2001-01-31	Us Health	Genes semelhantes a delta expressos em tumores neuroendocrinos
US5750652A (en) *	1994-01-21	1998-05-12	Yale University	Deltex proteins
US5599576A (en) *	1995-02-06	1997-02-04	Surface Solutions Laboratories, Inc.	Medical apparatus with scratch-resistant coating and method of making same
EP0861261B9 (en) *	1995-06-28	2010-02-24	Imperial Cancer Research Technology Limited	Nucleotide and protein sequences of vertebrate delta genes and methods based thereon
US5780300A (en) *	1995-09-29	1998-07-14	Yale University	Manipulation of non-terminally differentiated cells using the notch pathway
US20050158859A1 (en) *	1995-09-29	2005-07-21	Yale University	Manipulation of non-terminally differentiated cells using the Notch pathway
DE69635899T2 (de) *	1995-11-17	2006-11-23	Asahi Kasei Kabushiki Kaisha	Polypeptid, das die differenzierung unterdrueckt
AU728798B2 (en) *	1995-11-22	2001-01-18	Yale University	Vertebrate deltex proteins, nucleic acids, and antibodies, and related methods and compositions
AU720890B2 (en) *	1996-05-31	2000-06-15	National American Red Cross, The	Therapeutic and diagnostic methods and compositions based on jagged/notch proteins and nucleic acids
EP0939814A1 (en) *	1996-10-21	1999-09-08	HSC Research and Development Limited Partnership	Fringe proteins and notch signalling
CZ295997B6 (cs) *	1996-11-07	2005-12-14	Lorantis Limited	Farmaceutický prostředek s obsahem ligandu Notch a způsob tvorby T-buněk
EP0972041B2 (en) *	1997-04-04	2017-01-18	Millennium Pharmaceuticals, Inc.	Novel human delta3 compositions and therapeutic and diagnostic uses therefor
JP4171528B2 (ja) *	1997-05-14	2008-10-22	旭化成株式会社	新規な分化抑制剤
US6136952A (en) *	1997-06-25	2000-10-24	University Of Washington	Human jagged polypeptide, encoding nucleic acids and methods of use
US6436650B1 (en) *	1997-07-23	2002-08-20	Yale University	Activated forms of notch and methods based thereon
US6692919B1 (en) *	1997-07-23	2004-02-17	Yale University	Activated forms of notch and methods based thereon
US8084258B2 (en) *	1999-07-12	2011-12-27	University Of Basel	Manipulation of tissue of organ type using the notch pathway
US7399633B2 (en) *	2000-10-27	2008-07-15	Fred Hutchinson Cancer Research Center	Methods for immortalizing cells

1995
- 1995-09-29 US US08/537,210 patent/US5780300A/en not_active Expired - Lifetime
1996
- 1996-09-27 JP JP09513747A patent/JP2000511043A/ja not_active Withdrawn
- 1996-09-27 EP EP96933960.5A patent/EP0948348B1/en not_active Expired - Lifetime
- 1996-09-27 WO PCT/US1996/015651 patent/WO1997011716A1/en not_active Ceased
- 1996-09-27 AU AU72649/96A patent/AU732629B2/en not_active Expired
- 1996-09-27 CA CA2233534A patent/CA2233534C/en not_active Expired - Lifetime
1998
- 1998-07-10 US US09/113,825 patent/US6149902A/en not_active Expired - Lifetime
2003
- 2003-04-18 US US10/419,026 patent/US20040058443A1/en not_active Abandoned
2006
- 2006-11-28 US US11/605,536 patent/US20070166824A1/en not_active Abandoned
2009
- 2009-01-07 JP JP2009001970A patent/JP2009143934A/ja active Pending

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2015004762A1 (ja) *	2013-07-10	2015-01-15	株式会社日立製作所	細胞培養方法、装置、及び細胞シート
JP2020072694A (ja) *	2014-06-04	2020-05-14	フレッドハッチンソンキャンサーリサーチセンター	Ｎｏｔｃｈ１および／またはＮｏｔｃｈ２アゴニストを用いた幹細胞の増殖および生着
JP7121720B2 (ja)	2014-06-04	2022-08-18	フレッドハッチンソンキャンサーリサーチセンター	Ｎｏｔｃｈ１および／またはＮｏｔｃｈ２アゴニストを用いた幹細胞の増殖および生着
JP2018506293A (ja) *	2015-02-24	2018-03-08	ザリージェンツオブザユニバーシティオブカリフォルニア	結合誘発型転写スイッチ及びその使用方法
JP2021019625A (ja) *	2015-02-24	2021-02-18	ザリージェンツオブザユニバーシティオブカリフォルニア	結合誘発型転写スイッチ及びその使用方法
JP2022145748A (ja) *	2015-02-24	2022-10-04	ザリージェンツオブザユニバーシティオブカリフォルニア	結合誘発型転写スイッチ及びその使用方法
JP7357731B2 (ja)	2015-02-24	2023-10-06	ザリージェンツオブザユニバーシティオブカリフォルニア	結合誘発型転写スイッチ及びその使用方法
JP2023165849A (ja) *	2015-02-24	2023-11-17	ザリージェンツオブザユニバーシティオブカリフォルニア	結合誘発型転写スイッチ及びその使用方法
JP7719836B2 (ja)	2015-02-24	2025-08-06	ザリージェンツオブザユニバーシティオブカリフォルニア	結合誘発型転写スイッチ及びその使用方法
JP7719836B6 (ja)	2015-02-24	2025-09-18	ザリージェンツオブザユニバーシティオブカリフォルニア	結合誘発型転写スイッチ及びその使用方法

Also Published As

Publication number	Publication date
EP0948348B1 (en)	2014-01-01
CA2233534C (en)	2012-06-05
CA2233534A1 (en)	1997-04-03
JP2009143934A (ja)	2009-07-02
US5780300A (en)	1998-07-14
WO1997011716A1 (en)	1997-04-03
EP0948348A1 (en)	1999-10-13
US20040058443A1 (en)	2004-03-25
US20070166824A1 (en)	2007-07-19
US6149902A (en)	2000-11-21
AU732629B2 (en)	2001-04-26
EP0948348A4 (en)	2002-05-22
AU7264996A (en)	1997-04-17

Legal Events

Date	Code	Title	Description
2007-08-14	A131	Notification of reasons for refusal	Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070814
2007-11-29	A601	Written request for extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20071108
2007-12-17	A602	Written permission of extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20071217
2008-03-06	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080214
2008-03-25	A131	Notification of reasons for refusal	Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080325
2008-07-10	A601	Written request for extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080623
2008-07-28	A602	Written permission of extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080728
2008-08-14	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080725
2008-09-09	A02	Decision of refusal	Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20080909
2009-01-08	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090107
2009-02-05	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20090109
2009-02-25	A911	Transfer to examiner for re-examination before appeal (zenchi)	Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20090226
2009-03-10	A912	Re-examination (zenchi) completed and case transferred to appeal board	Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20090305
2009-11-26	A601	Written request for extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20091125
2009-12-01	A602	Written permission of extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20091130
2011-05-27	A601	Written request for extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110526
2011-06-01	A602	Written permission of extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110531
2011-07-02	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110701
2011-12-28	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20111227
2011-12-28	A761	Written withdrawal of application	Free format text: JAPANESE INTERMEDIATE CODE: A761 Effective date: 20111227
2011-12-28	RD02	Notification of acceptance of power of attorney	Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20111227
2012-01-21	RD04	Notification of resignation of power of attorney	Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20111227

Publication	Publication Date	Title
CA2233534C (en)	2012-06-05	Manipulation of non-terminally differentiated cells using the notch pathway
US7399633B2 (en)	2008-07-15	Methods for immortalizing cells
US8084258B2 (en)	2011-12-27	Manipulation of tissue of organ type using the notch pathway
Liang et al.	2018	A branching morphogenesis program governs embryonic growth of the thyroid gland
Hadeball et al.	1998	Xenopus cadherin-11 (Xcadherin-11) expression requires the Wg/Wnt signal
US20050158859A1 (en)	2005-07-21	Manipulation of non-terminally differentiated cells using the Notch pathway
JPH09509574A (ja)	1997-09-30	脊索によって発現されるヘッジホッグ、Ｖｈｈ−１、の脊椎動物相同体をコードするＤＮＡ、及びこれらの使用
Malhotra et al.	2009	Canonical Wnt pathway signaling suppresses VCAM-1 expression by marrow stromal and hematopoietic cells
Uezu et al.	2019	Essential role for InSyn1 in dystroglycan complex integrity and cognitive behaviors in mice
Tao et al.	2010	Efficient generation of mature cerebellar Purkinje cells from mouse embryonic stem cells
JP4652645B2 (ja)	2011-03-16	Ｎｏｔｃｈ経路を用いた組織型または器官型の操作
JP2011019520A (ja)	2011-02-03	Ｎｏｔｃｈ経路を用いた組織型または器官型の操作
Ratzan	2021	Mechanisms that Pattern the Sensory Epithelia in the Developing Vestibular System
WO2012035309A1 (en)	2012-03-22	Methods
Todd	2020	There and back again: functional outcomes of reciprocal neuron-astrocyte signalling
Guo	2008	Maintenance, differentiation and regulation of multipotent progenitor cells in the olfactory epithelium
Orentas	1997	The determination and development of glia originating from the ventral midline of the vertebrate neural tube
Tereshchenko	2008	Neural stem cells from embryonic brain of mice and neural cell adhesion molecule L1 and projection aberrations to the hippocampus in NCAM deficient mice (Mus musculus L., 1758)
Yuliya	2008	Neural stem cells from embryonic brain of mice and neural cell adhesion molecule L1 and projection aberrations to the hippocampus in NCAM deficient mice (Mus musculus L., 1758)
Wanga	2002	Expression of NK2 homologs and cardiomyocyte differentiation during zebrafish development: Analysis of 8-26 somite stages
dos Santos Carvalho	2016	Morpho-functional impact of Vangl2 on hippocampus development
Miller	2008	Regional specialization & developmental regulation of neocortical firing types
Singhal	2007	Investigation into the application of adult human Mueller stem cells in retinal ganglion cell replacement therapy
WILLEMS	2011	Cellular and molecular control of skeleton formation in fish: Insights from osteoblast ablation and functional characterization of Lrp5 and SOst
Burns	2005	Mechanisms of differentiation and proliferation during development of specialized forebrain structures